recast-jats-buildd8e1462159jitcJ Immunother CancerjitcJournal for ImmunoTherapy of CancerJ Immunother CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltdjitc-2019-000391corr110.1136/jitc-2019-000391corr132661117/jitc/8/2/e000391corr1.atomCorrectionOpen accessSpecial collectionsOpen accessCorrection: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 7202097202029620202962020127202082e000391corr1© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.2020https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.special-featureunlocked

Ascierto PA, Del Vecchio M, Mackiewicz A, et al. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. J ImmunoTher Cancer 2020;8:e000391. doi: 10.1136/jitc-2019-000391

Since the online publication of this article, it was noticed that ‘Michele Del Vecchio’ was incorrectly spelt as ‘Michelle Del Vecchio’. This error has been corrected.